Amgen Inc. (NASDAQ:AMGN) Stock Holdings Boosted by Guardian Investment Management

Guardian Investment Management grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 29.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 18,358 shares of the medical research company’s stock after buying an additional 4,179 shares during the period. Amgen accounts for approximately 3.3% of Guardian Investment Management’s holdings, making the stock its 6th biggest holding. Guardian Investment Management’s holdings in Amgen were worth $4,785,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Grove Bank & Trust raised its stake in shares of Amgen by 3.5% during the fourth quarter. Grove Bank & Trust now owns 2,750 shares of the medical research company’s stock valued at $717,000 after purchasing an additional 93 shares during the period. Brady Martz Wealth Solutions LLC bought a new stake in shares of Amgen in the fourth quarter worth $1,245,000. My Legacy Advisors LLC raised its holdings in Amgen by 5.0% in the fourth quarter. My Legacy Advisors LLC now owns 3,065 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 147 shares in the last quarter. Steigerwald Gordon & Koch Inc. boosted its stake in Amgen by 0.6% during the 4th quarter. Steigerwald Gordon & Koch Inc. now owns 70,450 shares of the medical research company’s stock valued at $18,362,000 after acquiring an additional 434 shares during the last quarter. Finally, Liberty One Investment Management LLC grew its holdings in Amgen by 9.3% during the 4th quarter. Liberty One Investment Management LLC now owns 14,895 shares of the medical research company’s stock worth $3,882,000 after acquiring an additional 1,264 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AMGN. Redburn Partners lowered their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Piper Sandler reduced their price objective on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Truist Financial dropped their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Finally, TD Cowen boosted their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.91.

Amgen Trading Up 1.0 %

Shares of AMGN stock opened at $272.11 on Monday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm’s fifty day simple moving average is $273.95 and its 200 day simple moving average is $307.20. The firm has a market capitalization of $146.27 billion, a P/E ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the business earned $4.96 EPS. The firm’s revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts predict that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.